Kidney Function Restoration Program

Alternative Cure for Kidney Disease

Get Instant Access

1. Handelsman DJ. Hypothalamic-pituitary gonadal dysfunction in chronic renal failure, dialysis, and renal transplantation. Endocr Rev 1985;6:151-182.

2. Handelsman DJ, Liu PY. Androgen therapy in chronic renal failure. Baillieres Clin Endocrinol Metab 1998;12:485-500.

3. Nieschlag E, Nieschlag S, Behre HM. Lifespan and testosterone. Nature 1993;366:215.

4. Anonymous. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1996;7:198-207.

5. Fung L, Pollock CA, Caterson RJ, et al. Dialysis adequacy and nutrition determine prognosis in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 1996;7:737-744.

6. Kopple JD. Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis 1994;24:1002-1009.

7. Dombros NV, Digenis GE, Soliman G, Oreopoulos DG. Anabolic steroids in the treatment of malnourished CAPD patients: a retrospective study. Peritoneal Dialysis Int 1994;14:344-347.

8. Navarro JF, Mora-Fernandez C, Rivero A, et al. Androgens for the treatment of anemia in peritoneal dialysis patients. Adv Peritoneal Dialysis 1998;14:232-235.

9. Gascon A, Belvis JJ, Berisa F, Iglesias E, Estopinan V, Teruel JL. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. Geriatr Nephrol Urol 1999;9:67-72.

10. Cianciaruso B, Brunori G, Kopple JD, et al. Cross-sectional comparison of malnutrition in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am J Kidney Dis 1995;26:475-486.

11. Handelsman DJ. The safety of androgens: prostate and cardiovascular disease. In: Wang C, ed. Male Reproductive Function. Kluwer Academic Publishers, Boston, 1998, pp. 227-237.

12. Handelsman DJ, Dong Q. Hypothalamo-pituitary gonadal axis in chronic renal failure. Endocrinol Metab Clin North Am 1993;22:145-161.

13. Veldhuis JD, Wilkowski MJ, Zwart AD, et al. Evidence for attenuation of hypothalamic gonadotropin-releasing hormone (GnRH) impulse strength with preservation of GnRH pulse frequency in men with chronic renal failure. J Clin Endocrinol Metab 1993;76:648-654.

14. De Celis R, Pedron-Nuevo N. Male fertility of kidney transplant patients with one to ten years of evolution using a conventional immunosuppressive regimen. Arch Androl 1999;42:9-20.

15. Ramirez G, Narvarte J, Bittle PA, Ayers-Chastain C, Dean SE. Cyclosporine-induced alterations in the hypothalamic hypophyseal gonadal axis in transplant patients. Nephron 1991;58:27-32.

16. Jecht E, Klupp E, Heidler R, Huben H, Schwarz W. Investigation of the hormonal axis hypothalamus-pituitary-gonads in 20 dialyzed men. Andrologia 1980;12:146-155.

17. Stewart-Bentley M, Gans D, Horton R. Regulation of gonadal function in uremia. Metab Clin Exp 1974;23:1065-1072.

18. Handelsman DJ, Ralec VL, Tiller DJ, Horvath JS, Turtle JR. Testicular function after renal transplantation. Clin Endocrinol 1981;14:527-538.

19. Holdsworth S, Atkins RC, de Kretser DM. The pituitary-testicular axis in men with chronic renal failure. N Engl J Med 1977;296:1245-1249.

20. Lim VS, Fang VS. Restoration of plasma testosterone levels in uremic men with clomiphene citrate. J Clin Endocrinol Metab 1976;43:1370-1377.

21. Dunkel L, Raivio T, Laine J, Holmberg C. Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney Int 1997;51:777-784.

22. Rodger R, Morrison L, Dewar J, Wilkinson R, Ward M, Kerr D. Loss of pulsatile luteinizing hormone secretion in men with chronic renal failure. Br Med J 1985;291:1598-1600.

23. Wheatley T, Clark P, Raggatt P, Evans D, Holder R. Pulsatility of luteinising hormone in men with chronic renal failure: abnormal rather than absent. Br Med J 1987;294:482.

24. Talbot JA, Rodger RSC, Robertson WR. Pulsatile bioactive luteinising hormone secretion in men with chronic renal failure and following renal transplantation. Nephron 1990;56:66-72.

25. Schaefer F, Seidel C, Mitchell R, Scharer K, Robertson WR, Cooperative Study Group on Pubertal Development in Chronic Renal Failure (CSPCRF). Pulsatile immunoreactive and bioactive luteinizing hormone secretion in adolescents with chronic renal failure. Pediatr Nephrol 1991;5:566-571.

26. Schaefer F, Veldhuis JD, Robertson WR, Dunger D, Scharer K. Immunoreactive and bioactive luteinizing hormone in pubertal patients with chronic renal failure. Kidney Int 1994;45:1465-1476.

27. Handelsman DJ, Spaliviero JA, Turtle JR. Bioactive luteinizing hormone in plasma of uraemic men and men with primary testicular damage. Clin Endocrinol 1986;24:259-266.

28. Mitchell R, Bauerfeld C, Schaefer F, Scharer K, Robertson WR. Less acidic forms of luteinizing hormone are associated with lower testosterone secretion in men on haemodialysis treatment. Clin Endocrinol 1994;41:65-73.

29. Bundschu HD, Rager K, Heller S, et al. Auswirkungen einer langdaueren exogenen Gonadotropinzufuhr auf die testikulare Insuffizienz bei Dauerdialysepatienten. Klinische Wochen-schricht 1976;54:1039-1046.

30. Canale D, Barsantini S, Minervini R, Fiorentini L, Barsotti G, Menchini-Fabris GF. Human chorionic gonadotropin treatment of male sexual inadequacy in patients affected by chronic renal failure. J Androl 1984;5:120-124.

31. Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomised clinical trial of recombinant human chorionic gonadotropin (r-hCG) on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2002;87:3125-3135.

32. Martin-Malo A, Benito P, Castillo D, et al. Effect of clomiphene citrate on hormonal profile in male hemodialysis and kidney transplant patients. Nephron 1993;63:390-394.

33. Sharpe RM. Do males rely on female hormones? Nature 1997;390:447-448.

34. van Coevorden A, Stolear JC, Dhaene M, Herweghem JLv, Mockel J. Effect of chronic oral testosterone undecanoate administration on the pituitary-testicular axes of hemodialyzed male patients. Clin Nephrol 1986;26:48-54.

35. Singh AB, Norris K, Modi N, et al. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. J Clin Endocrinol Metab 2001;86:2437-2445.

36. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial [see comments]. JAMA 1999;281:1275-1281.

37. McNair DM, Lorr M, Droppleman LF. EITS manual for the profile of mood states. Educational and Industrial Testing Service, San Diego, 1971.

38. Segarra A, Chacon P, Vilardell M, Piera LL. Prospective case-control study to determine the effects of lovastatin on serum testosterone and cortisol concentrations in hyperlipidemic nephrotic patients with chronic renal failure. Nephron 1996;73:186-190.

39. Zofkova I, Sotornik I, Kancheva RL. Adenohypophyseal-gonadal dysfunction in male haemodialyzed patients before and after subtotal parathyroidectomy. Nephron 1996;74:536-540.

40. Kopera H. Miscellaneous uses of anabolic steroids. In: Kochakian CD, ed. Anabolic-Androgenic Steroids. Vol. 43. Springer-Verlag, Berlin, 1976, pp. 535-625.

41. Kruskemper HL. Anabolic Steroids. Academic, New York, 1968, pp. 236.

42. Dontas AS, Papanicolaou NT, Papanayiotou P, Malamos BK. Long-term effects of anabolic steroids on renal functions in the aged subject. J Gerontol 1967;22:268-273.

43. Wilkey JL, Barson LJ, Kest L, Bragagni A. The effect of testosterone on the azotemic patient: an intermediary report. J Urol 1960;83:25-29.

44. Antus B, Yao Y, Liu S, Song E, Lutz J, Heemann U. Contribution of androgens to chronic allograft nephropathy is mediated by dihydrotestosterone. Kidney Int 2001;60:1955-1963.

45. Muller V, Szabo A, Viklicky O, et al. Sex hormones and gender-related differences: their influence on chronic renal allograft rejection. Kidney Int 1999;55:2011-2020.

46. Loh KC, Salisbury SR, Accott P, Gillis R, Crocker JF. Central precocious puberty and chronic renal failure: a reversible condition post renal transplantation. J Pediatr Endocrinol Metab 1997;10:539-545.

47. Kassmann K, Arsan A, Sharer K, Broyer M. Fonction gonadique et activite genitale des malades transplantes renaux de sexe masculin. Annales de Pediatre 1991;38:405-406.

48. Jones RWA, El Bishti MM, Bloom SR, et al. The effects of anabolic steroids on growth, body composition, and metabolism in boys with chronic renal failure on regular hemodialysis. J Pediatr 1980;97:559-566.

49. Van Steenbergen MW, Wit JM, Donckerwolcke RA. Testosterone esters advance skeletal maturation more than growth in short boys with chronic renal failure and delayed puberty. Eur J Pediatr 1991;150:676-680.

50. Rees L, Greene SA, Rigden SPA, Haycock GB, Chantler C, Preece MA. Oxandrolone for delayed puberty in boys taking long-term steroid therapy for renal disease. Pediatr Nephrol 1990;4:160-162.

51. Giusti M, Perfumo F, Verrina E, et al. Delayed puberty in uremia: pituitary-gonadal function during short-term pulsatile luteinizing hormone-releasing hormone administration. J Endocrinol Invest 1992;15:709-717.

52. Winkler L, Offner G, Krull F, Brodehl J. Growth and pubertal development in nephropathic cysti-nosis. Eur J Pediatr 1993;152:244-249.

53. Chik CL, Friedman A, Merriam GR, Gahl WA. Pituitary-testicular function in nephropathic cysti-nosis. Ann Intern Med 1993;119:568-575.

54. Kassmann K, Rappaport R, Broyer M. The short-term effect of testosterone on growth in boys on hemodialysis. Clin Nephrol 1992;37:148-154.

55. Steele TE, Wuerth D, Finkelstein S, et al. Sexual experience of the chronic peritoneal dialysis patient. J Am Soc Nephrol 1996;7:1165-1168.

56. Lawrence IG, Price DE, Howlett TA, Harris KP, Feehally J, Walls J. Correcting impotence in the male dialysis patient: experience with testosterone replacement and vacuum tumescence therapy. Am J Kidney Dis 1998;31:313-319.

57. Barton CH, Mirahmadi MK, Vaziri ND. Effects of long-term testosterone administration on pituitary-testicular axis in end-stage renal failure. Nephron 1982;31:61-64.

58. Chopp RT, Mendez R. Sexual function and hormonal abnormalities in uremic men on chronic dialysis and after renal transplantation. Fertil Steril 1978;29:661-666.

59. Brook AC, Ward MK, Cook DB, Johnston DG, Watson MJ, Kerr DNS. Absence of a therapeutic effect of zinc in the sexual dysfunction of haemodialysis patients. Lancet 1980;2:618-620.

60. Bommer J, del Pozo E, Ritz E, Bommer G. Improved sexual function in male haemodialysis patients on bromocryptine. Lancet 1979;2:496-497.

61. Zetin M, Frost NR, Brumfield D, Stone RA. Amitryptiline stimulates weight gain in hemodialysis patients. Clin Nephrol 1982;18:79-82.

62. Yeksan M, Polat M, Turk S, et al. Effect of vitamin E therapy on sexual functions or uremic patients in hemodialysis. Int J Art Organs 1992;15:648-652.

63. Yeksan M, Tamer N, Cirit M, et al. Effect of recombinant human erythropoietin (r-HuEPO) therapy on plasma FT3, FT4, TSH, FSH, LH, free testosterone and prolactin levels in hemodialysis patients. Int J Art Organs 1992;5:585-589.

64. Lawrence IG, Price DE, Howlett TA, Harris KP, Feehally J, Walls J. Erythropoietin and sexual dysfunction. Nephrol Dialysis Transplant 1997;12:741-747.

65. Wu SC, Lin SL, Jeng FR. Influence of erythropoietin treatment on gonadotropic hormone levels and sexual function in male uremic patients. Scand J Urol Nephrol 2001;35:136-140.

66. Schaefer RM, Kokot F, Heidland A. Impact of recombinant erythropoietin on sexual function in hemodialysis patients. In: Baldamus CA, Scigalla P, Wieczorek L, Koch KM, eds. Erythropoietin: From Molecular Structure to Clinical Application. Vol. 76. Karger, Basel, 1989, pp. 273-282.

67. Kokot F, Wiecek A, Grzeszczak W, Klin M. Infleunce of erythropoietin treatment on follitropin and lutropin response to luliberin and plasma testosterone in haemodialysed patients. Nephron 1990;56:126-129.

68. Diez JJ, Iglesias P, Bajo MA, de Alvaro F, Selgas R. Effects of erythropoietin on gonadotropin responses to gonadotropin-releasing hormone in uremic patients. Nephron 1997;77:169-175.

69. Tokgoz B, Utas C, Dogukan A, et al. Effects of long-term erythropoietin therapy on the hypothalamo-pituitary-testicular axis in male CAPD patients. Perit Dial Int 2001;21:448-454.

70. Palmer BF. Sexual dysfunction in uremia. J Am Soc Nephrol 1999;10:1381.

71. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-1404.

72. MacDougall IC, Mahon A, Muir G, Sidhu P. Randomised placebo-controlled study of sildenafil (Viagra) in peritoneal dialysis patients with erectile dysfunction. J Am Soc Nephrol 1999;10:318A.

73. Chen J, Mabjeesh NJ, Greenstein A, Nadu A, Matzkin H. Clinical efficacy of sildenafil in patients on chronic dialysis. J Urology 2001;165:819-821.

74. Turk S, Karalezli G, Tonbul HZ, et al. Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dialysis Transplant 2001;16:1818-1822.

75. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996;334:873-877.

76. Mansi MK, Alkhudair WK, Huraib S. Treatment of erectile dysfunction after kidney transplantation with intracavernosal self-injection of prostaglandin E1. J Urol 1998;159:1927-1930.

77. Rodriguez Antolin A, Morales JM, Andres A, et al. Treatment of erectile impotence in renal transplant patients with intracavernosal vasoactive drugs. Transplant Proc 1992;24:105-106.

78. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group N Engl J Med 1997;336:1-7.

79. Prem AR, Punekar SV, Kalpana M, Kelkar AR, Acharya VN. Male reproductive function in uraemia: efficacy of haemodialysis and renal transplantation. Br J Urol 1996;78:635-638.

80. Maeda Y, Nakanishi T, Ozawa K, et al. Anabolic steroid-associated hypogonadism in male hemodialysis patients. Clin Nephrol 1989;32:198-201.

81. Neff MS, Goldberg J, Slifkin RF, et al. Anemia in chronic renal failure. Acta Endocrinol 1985;271(suppl):80-86.

82. Winearls CG. Historical review of the use of recombinant human erythropoietin in chronic renal failure. Nephrol Dialysis Transplant 1995;10(suppl 2):3-9.

83. Navarro JF, Mora C. In-depth review: effect of androgens on anemia and malnutrition in renal failure: implications for patients on peritoneal dialysis. Perit Dialysis Int 2001;21:14-24.

84. Weber JP, Walsh PC, Peters CA, Spivak JL. Effect of reversible androgen deprivation on hemoglobin and serum erythropoietin in men. Am J Hematol 1991;36:190-194.

85. Teruel JL, Cano T, Mareen R, et al. Decrease in the haemoglobin level in haemodialysis patients undergoing antiandrogen therapy. Nephrol Dialysis Transplant 1997;12:1262-1263.

86. von Hartitzsch B, Kerr DNS. Response to parenteral iron with and without androgen therapy in patients undergoing regular haemodialysis. Nephron 1976;17:430-438.

87. Teruel JL, Mareen R, Navarro JF, et al. Evolution of serum erythropoietin after androgen administration to hemodialysis patients: a prospective study. Nephron 1995;70:282-286.

88. Chan PCK, Wei DCC, Tam SCF, Chan FL, Yeung WC, Cheng IKP. Post-transplant erythrocytosis: role of erythropoietin and male sex hormones. Nephrol Dialysis Transplant 1992;7:137-142.

89. Foresta C, Mioni R, Bordon P, Miotto D, Montini G, Varotto A. Erythropoietin stimulates testosterone production in man. J Clin Endocrinol Metab 1994;78:753-756.

90. Hendler ED, Goffinet JA, Ross S, Longnecker RE, Bakovic V. Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis. N Engl J Med 1974;291:1046-1051.

91. Williams JS, Stein JH, Ferris TF. Nandrolone decanoate therapy for patients receiving hemodialysis. A controlled study. Arch Intern Med 1974;134:289-292.

92. Buchwald D, Argyres S, Easterling RE, et al. Effect of nandrolone decanoate on the anemia of chronic hemodialysis patients. Nephron 1977;18:232-238.

93. Bock EL, Fulle HH, Heimpel H, Pribilla W. Die Wirkung von Mesterolon bei Panmyelopathien und renalen Anaemien. Medizinische Klinik 1976;1:539-547.

94. Naik RB, Gibbons AR, Gyde OH, Harris BR, Robinson BH. Androgen trial in renal anaemia. Proc Eur Dialysis Transplant Assoc 1978;15:136-143.

95. Neff MS, Goldberg J, Slifkin RF, et al. A comparison of androgens for anemia in patients on hemodialysis. N Engl J Med 1981;304:871-875.

96. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991;17:29-33.

97. Teruel JL, Aguilera A, Marcen R, Antolin JN, Otero GG, Ortuno J. Androgen therapy for anaemia of chronic renal failure. Scand J Urol Nephrol 1996;30:403-408.

98. Teruel JL, Marcen R, Navarro-Antolin J, Aguilera A, Fernandez-Juarez G, Ortuno J. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study. J Am Soc Nephrol 1996;7:140-144.

99. Gaughan WJ, Liss KA, Dunn SR, et al. A 6-month study of low-dose recombinant human erythropoi-etin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 1997;30:495-500.

100. Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nan-drolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992;37:264-267.

101. Horl WH. Is there a role for adjuvant therapy in patients being treated with epoetin? Nephrol Dialysis Transplant 1999;14:50-60.

102. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriat Soc 1995;43:899-901.

103. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogo-nadal males: a retrospective analysis. J Clin Endocrinol Metab 1997;82:3793-3796.

104. Jockenhovel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 1997;2:293-298.

105. Powe NR, Griffiths RI, Bass EB. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease. J Am Soc Nephrol 1993;3:1610-1671.

106. Grunstein RR, Handelsman DJ, Lawrence SJ, Blackwell C, Caterson ID, Sullivan CE. Hypothalamic dysfunction in sleep apnea: reversal by nasal continuous positive airways pressure. J Clin Endocrinol Metab 1989;68:352-358.

107. Sandblom RE, Matsumoto AM, Scoene RB, et al. Obstructive sleep apnea induced by testosterone administration. N Engl J Med 1983;308:508-510.

108. Millman RP, Kimmel PL, Shore ET, Wasserstein AG. Sleep apnea in hemodialysis patients: the lack of testosterone effect on its pathogenesis. Nephron 1985;40:407-410.

109. Kimmel PL, Miller G, Mendelson WB. Sleep apnea syndrome in chronic renal disease. Am J Med 1989;86:308-314.

110. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;4:1966-1972.

111. Liu PY, Yee B, Wishart SM, Yang Q, Grunstein R, Handelsman DJ. The acute effects of high dose testosterone on sleep in ageing men [abstract]. US Endocrine Society, San Francisco, 2002.

112. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogo-nadal men in comparison to age-matched normal controls. Clin Endocrinol 1994;40:341-349.

113. Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol (Oxf) 2001;54:437-445.

114. Jin B, Turner L, Walters WAW, Handelsman DJ. Androgen or estrogen effects on the human prostate. J Clin Endocrinol Metab 1996;81:4290-4295.

115. Teruel JL, Aguilera A, Avila C, Ortuno J. Effects of androgen therapy on prostatic markers in hemodi-alyzed patients. Scand J Urol Nephrol 1996;30:129-131.

Was this article helpful?

0 0
Naturally Cure Erectile Dysfunction

Naturally Cure Erectile Dysfunction

Whether we like it or not, for many men it gets increasingly difficult to perform sexually as the years advance.

Get My Free Ebook

Post a comment